home / stock / inmb / inmb news

INMB News and Press, INmune Bio Inc. From 05/09/24

Stock Information
Company Name: INmune Bio Inc.
Stock Symbol: INMB
Market: NYSE
Website: inmunebio.com
Menu
INMB INMB Quote INMB Short INMB News INMB Articles INMB Message Board
Get INMB Alerts

News, Short Squeeze, Breakout and More Instantly...
INMB - INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial resu...
INMB - Expected US Company Earnings on Thursday, May 9th, 2024

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

INMB - Expected US Company Earnings on Wednesday, May 8th, 2024

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

INMB - INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a ...
INMB - INmune Bio files for $250M mixed shelf offering

2024-05-01 16:50:15 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript INmune Bio provides update on Alzheimer's candidate XPro INmune Bio rises 2%, on $4.5M direct offeri...

INMB - Expected US Company Earnings on Wednesday, May 1st, 2024

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

INMB - INmune Bio provides update on Alzheimer's candidate XPro

2024-04-30 09:33:34 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript INmune Bio rises 2%, on $4.5M direct offering Seeking Alpha’s Quant Rating on INmune Bio ...
INMB - INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro(TM) Under Compassionate Use for Over Three Years

Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an up...

INMB - INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune(TM) Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, continues to advance its Nat...

INMB - INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced today t...
Previous 10 Next 10